Clinical trial registry record

Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 28, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07531927
Last registry update
July 28, 2026
Status
Recruiting
Phase
Phase not reported
Sponsor
Okuvision GmbH
Enrollment
70
Countries
Germany
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
70
Population
ALL · 60 Years
Duration
2026-05-05 to 2028-06-01
Intervention
Transcorneal electrical stimulation (TES) with the OkuStim 2 System
Comparator
Not reported
Outcomes measured
Safety of TES therapy in GA — From enrolment until the end of the study for the individual participant at 52 weeks; Effects of TES therapy with two different stimulus waveforms on the progression of GA lesion areas — At 12 months and a…; Effects of TES therapy with two different stimulus waveforms on structural changes in retinal layers — At 12 months and…; Effects of TES therapy with two different stimulus waveforms on functional changes in the border zone of GA areas — At…; Effects of TES therapy with two different stimulus waveforms on visual acuity under normal luminance conditions — At 12…; Effects of TES therapy with two different stimulus waveforms on visual acuity under low-luminance conditions — At 12 mo…; Effects of TES therapy with two different stimulus waveforms on patient-reported outcomes regarding the impact on daily…; Effects of TES therapy with two different stimulus waveforms on patient-reported outcome regarding the applicability of…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON